Evolving Castration Resistance and Prostate Specific Membrane Antigen Expression: Implications for Patient Management.
177Lu-PSMA-RLT
PSMA
mCRPC
metastatic castration-resistant prostate cancer
prostate-specific membrane antigen
theranostics
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
16 Jul 2021
16 Jul 2021
Historique:
received:
28
06
2021
revised:
09
07
2021
accepted:
12
07
2021
entrez:
24
7
2021
pubmed:
25
7
2021
medline:
25
7
2021
Statut:
epublish
Résumé
Metastatic castration-resistant prostate cancer (mCRPC) remains an incurable disease, despite multiple novel treatment options. The role of prostate-specific membrane antigen (PSMA) in the process of mCRPC development has long been underestimated. During the last years, a new understanding of the underlying molecular mechanisms of rising PSMA expression and its association with disease progression has emerged. Accurate understanding of these complex interactions is indispensable for a precise diagnostic process and ultimately successful treatment of advanced prostate cancer. The combination of different novel therapeutics such as androgen deprivation agents, 177LU-PSMA radioligand therapy and PARP inhibitors promises a new kind of efficacy. In this review, we summarize the current knowledge about the most relevant molecular mechanisms around PSMA in mCRPC development and how they can be implemented in mCRPC management.
Identifiants
pubmed: 34298770
pii: cancers13143556
doi: 10.3390/cancers13143556
pmc: PMC8307676
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Urology. 2006 Sep;68(3):593-8
pubmed: 16979731
Urology. 1996 Aug;48(2):326-34
pubmed: 8753752
Endocr Relat Cancer. 2018 Oct 1;26(2):131-146
pubmed: 30400059
Lancet. 2020 Apr 11;395(10231):1208-1216
pubmed: 32209449
J Clin Oncol. 2008 Jan 10;26(2):242-5
pubmed: 18182665
Sci Rep. 2020 Apr 21;10(1):6681
pubmed: 32317750
Prostate Cancer Prostatic Dis. 2021 May 30;:
pubmed: 34054128
Genomics. 2001 May 1;73(3):243-54
pubmed: 11350116
J Cell Biochem. 2004 Feb 15;91(3):528-39
pubmed: 14755683
Nat Rev Urol. 2018 Apr;15(4):222-234
pubmed: 29460925
Nat Commun. 2017 Aug 29;8(1):374
pubmed: 28851861
Br J Cancer. 2011 Jun 7;104(12):1920-8
pubmed: 21559022
Ann Epidemiol. 2018 May;28(5):328-330
pubmed: 29678312
PLoS One. 2013;8(4):e61020
pubmed: 23565295
Eur Urol Focus. 2021 Mar;7(2):234-237
pubmed: 33172774
Clin Cancer Res. 1996 Sep;2(9):1445-51
pubmed: 9816319
Oral Surg Oral Med Oral Pathol Oral Radiol. 2018 May;125(5):478-486
pubmed: 29523427
J Clin Oncol. 2005 Apr 20;23(12):2754-62
pubmed: 15837990
Int J Clin Pract. 2011 Nov;65(11):1180-92
pubmed: 21995694
Prostate Cancer Prostatic Dis. 2020 Dec;23(4):549-560
pubmed: 32367009
Mol Imaging. 2018 Jan-Dec;17:1536012118776068
pubmed: 29873291
Mod Pathol. 2008 Dec;21(12):1421-7
pubmed: 18839017
J Nucl Med. 2018 Jun;59(6):929-933
pubmed: 29419479
Proc Natl Acad Sci U S A. 2011 Jun 7;108(23):9578-82
pubmed: 21606347
J Clin Oncol. 2016 Apr 20;34(12):1402-18
pubmed: 26903579
Theranostics. 2020 Jun 18;10(17):7645-7655
pubmed: 32685010
Cancers (Basel). 2019 Sep 12;11(9):
pubmed: 31547436
Sci Signal. 2017 May 23;10(480):
pubmed: 28536297
Cancer Res. 1998 Sep 15;58(18):4055-60
pubmed: 9751609
Mol Cancer. 2019 Feb 19;18(1):26
pubmed: 30782187
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):496-508
pubmed: 29247284
Cancer Cell Int. 2013 Jun 27;13(1):66
pubmed: 23805779
Sci Signal. 2017 Mar 14;10(470):
pubmed: 28292957
Endocr Relat Cancer. 2021 Jul 15;28(8):T19-T38
pubmed: 34128827
Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):687-694
pubmed: 31901103
Intern Med J. 2014 May;44(5):433-40
pubmed: 24816306
Biochim Biophys Acta. 2015 Oct;1848(10 Pt B):2502-11
pubmed: 25150047
Prostate. 2015 Feb 15;75(3):242-54
pubmed: 25327687
Circ Res. 2000 Jun 9;86(11):1129-34
pubmed: 10850963
Hum Mol Genet. 2000 Nov 22;9(19):2837-44
pubmed: 11092759
Am J Cancer Res. 2019 Jul 01;9(7):1309-1328
pubmed: 31392072
Prostate. 2006 Jun 1;66(8):867-75
pubmed: 16496414
Cells. 2020 Oct 21;9(10):
pubmed: 33096754
Eur Urol. 2019 Oct;76(4):469-478
pubmed: 31345636
J Exp Med. 2018 Jan 2;215(1):159-175
pubmed: 29141866
J Clin Oncol. 2019 Nov 10;37(32):2974-2986
pubmed: 31329516
Theranostics. 2019 Jul 9;9(17):4841-4848
pubmed: 31410185
Urol Oncol. 2014 Apr;32(3):272-9
pubmed: 24321253
Mol Cancer Res. 2016 Nov;14(11):1045-1053
pubmed: 27458033
J Urol. 2021 May;205(5):1361-1371
pubmed: 33356529
South Med J. 2015 Apr;108(4):224-8
pubmed: 25871992
Cancer Res. 2003 May 15;63(10):2645-8
pubmed: 12750292
Cancers (Basel). 2019 Sep 20;11(10):
pubmed: 31547070
Can J Urol. 2021 Jun;28(3):10673-10677
pubmed: 34129460
J Urol. 2004 Sep;172(3):910-4
pubmed: 15310996
Adv Exp Med Biol. 2006;576:327-37; discussion 361-3
pubmed: 16802724
Cancer Res. 1994 Apr 1;54(7):1807-11
pubmed: 7511053
J Nucl Med. 2017 Oct;58(10):1624-1631
pubmed: 28408529
Sci Rep. 2018 Mar 9;8(1):4254
pubmed: 29523813
Nat Rev Clin Oncol. 2020 Jun;17(6):337
pubmed: 32249842
Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3439-43
pubmed: 7724580
Am Soc Clin Oncol Educ Book. 2020 May;40:e319-e332
pubmed: 32479115
Nucl Med Biol. 2019 May - Jun;72-73:20-25
pubmed: 31260881
Cancer Cell. 2011 May 17;19(5):575-86
pubmed: 21575859
Sci Rep. 2019 Dec 27;9(1):20041
pubmed: 31882829
Cochrane Database Syst Rev. 2019 Jun 11;6:CD003506
pubmed: 31194882
J Nucl Med. 2020 May;61(5):723-728
pubmed: 31601703
Endocr Relat Cancer. 2013 May 20;20(3):R83-99
pubmed: 23456430
Lancet. 2010 Oct 2;376(9747):1147-54
pubmed: 20888992
Fertil Steril. 2001 Feb;75(2):252-9
pubmed: 11172823
Eur J Histochem. 2013 Apr 15;57(2):e13
pubmed: 23807292
Eur J Nucl Med Mol Imaging. 2020 Aug;47(9):2106-2112
pubmed: 32062682
Oncotarget. 2016 Jun 7;7(23):34930-41
pubmed: 27145459
Clin Genitourin Cancer. 2021 Feb 9;:
pubmed: 33678552
J Nucl Med. 2017 Sep;58(Suppl 2):67S-76S
pubmed: 28864615
Clin Nucl Med. 2018 Aug;43(8):609-610
pubmed: 29762244
Curr Pharm Des. 2020;26(31):3783-3798
pubmed: 32067601
Biochim Biophys Acta Rev Cancer. 2018 Dec;1870(2):198-206
pubmed: 30300679
Cancer Chemother Pharmacol. 2019 Dec;84(6):1289-1301
pubmed: 31549216
Urology. 2013 Dec;82(6):1197-203
pubmed: 23992971
Cancer Rep (Hoboken). 2019 Aug;2(4):e1169
pubmed: 32721116
Semin Nucl Med. 2019 Jul;49(4):313-325
pubmed: 31227054
JAMA. 2017 Jun 27;317(24):2532-2542
pubmed: 28655021
Histopathology. 2007 Mar;50(4):472-83
pubmed: 17448023
Proc Natl Acad Sci U S A. 1996 Jan 23;93(2):749-53
pubmed: 8570628
J Nucl Med. 2017 Jan;58(1):85-90
pubmed: 27765862
N Engl J Med. 2004 Oct 7;351(15):1502-12
pubmed: 15470213
Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):243-246
pubmed: 29134280
Prostate Cancer Prostatic Dis. 2020 Sep;23(3):441-448
pubmed: 31932660
Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):9-15
pubmed: 31654093
Prostate Cancer Prostatic Dis. 2020 Mar;23(1):38-52
pubmed: 31595044
Urol Oncol. 1995 Jan-Feb;1(1):18-28
pubmed: 21224086
Am Soc Clin Oncol Educ Book. 2019 Jan;39:321-330
pubmed: 31099673
J Investig Med High Impact Case Rep. 2020 Jan-Dec;8:2324709620941313
pubmed: 32646251
EJNMMI Radiopharm Chem. 2021 Feb 26;6(1):10
pubmed: 33638060
Cancer. 1998 Jun 1;82(11):2256-61
pubmed: 9610707
Medicine (Baltimore). 2020 Apr;99(15):e19760
pubmed: 32282738
J Nucl Med. 2021 Jul 1;62(7):975-978
pubmed: 33246977
Clin Cancer Res. 2003 Dec 15;9(17):6357-62
pubmed: 14695135
Cancer. 2017 Sep 15;123(18):3532-3539
pubmed: 28608931
PLoS One. 2020 Jan 27;15(1):e0226219
pubmed: 31986176
Clin Cancer Res. 1997 Jan;3(1):81-5
pubmed: 9815541
Proc Natl Acad Sci U S A. 2019 Jul 16;116(29):14573-14582
pubmed: 31266892
EJNMMI Res. 2018 Oct 29;8(1):96
pubmed: 30374743
J Nucl Med. 2020 May;61(5):689-695
pubmed: 31653712
PLoS One. 2009;4(2):e4608
pubmed: 19242540
Cells. 2020 Jun 22;9(6):
pubmed: 32580469
Lancet Oncol. 2018 Jun;19(6):825-833
pubmed: 29752180
N Engl J Med. 2021 Jun 23;:
pubmed: 34161051
CA Cancer J Clin. 2015 Jul-Aug;65(4):265-82
pubmed: 25958817
Cancer Discov. 2012 Dec;2(12):1134-49
pubmed: 22993403
Aktuelle Urol. 2009 Mar;40(2):100-8
pubmed: 19253209
N Engl J Med. 2020 May 28;382(22):2091-2102
pubmed: 32343890
Nat Rev Urol. 2018 Aug;15(8):468
pubmed: 29789593
Clin Nucl Med. 2017 May;42(5):410-413
pubmed: 28240661
J Nucl Med. 2020 Jun;61(6):904-910
pubmed: 31806771
Theranostics. 2016 Apr 28;6(8):1085-95
pubmed: 27279903
Clin Transl Imaging. 2018;6(2):145-148
pubmed: 29670866
Mol Cell Biol. 2006 Jul;26(14):5310-24
pubmed: 16809768
Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2045-2054
pubmed: 29980832
Theranostics. 2020 Jun 19;10(17):7812-7820
pubmed: 32685021
N Engl J Med. 2015 Oct 29;373(18):1697-708
pubmed: 26510020
Mol Biol Cell. 2003 Dec;14(12):4835-45
pubmed: 14528023
Prostate Cancer Prostatic Dis. 2021 Mar 21;:
pubmed: 33746213
Cells. 2020 Oct 22;9(11):
pubmed: 33105713
Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2354-63
pubmed: 24130224
PLoS One. 2013 Jul 25;8(7):e68339
pubmed: 23935860
Curr Nutr Rep. 2018 Sep;7(3):70-84
pubmed: 30099693
Biochim Biophys Acta. 1998 Nov 26;1443(1-2):113-27
pubmed: 9838072
Urology. 1998 Oct;52(4):637-40
pubmed: 9763084
J Nucl Med. 2018 Jul;59(7):1007-1013
pubmed: 29674422
Front Oncol. 2018 Dec 20;8:623
pubmed: 30619757
Cancer Cell. 2013 Jan 14;23(1):35-47
pubmed: 23260764
Transl Androl Urol. 2020 Apr;9(2):837-839
pubmed: 32420195
Clin Nucl Med. 2016 Jul;41(7):522-8
pubmed: 27088387
Diagnostics (Basel). 2021 Mar 08;11(3):
pubmed: 33800158
Prostate. 2011 Feb 15;71(3):281-8
pubmed: 20809553
Urologe A. 2020 Jun;59(6):680-686
pubmed: 32333064
Nat Rev Cancer. 2011 Jul 22;11(8):609-18
pubmed: 21779011
J Oncol. 2020 Sep 7;2020:4986365
pubmed: 32963528